Candel Therapeutics (CADL) Accumulated Depreciation: 2020-2023
Historic Accumulated Depreciation for Candel Therapeutics (CADL) over the last 3 years, with Sep 2023 value amounting to $1.8 million.
- Candel Therapeutics' Accumulated Depreciation rose 102.42% to $1.8 million in Q3 2023 from the same period last year, while for Sep 2023 it was $1.8 million, marking a year-over-year increase of 102.42%. This contributed to the annual value of $1.1 million for FY2022, which is 220.74% up from last year.
- Latest data reveals that Candel Therapeutics reported Accumulated Depreciation of $1.8 million as of Q3 2023, which was up 15.36% from $1.6 million recorded in Q2 2023.
- In the past 5 years, Candel Therapeutics' Accumulated Depreciation ranged from a high of $1.8 million in Q3 2023 and a low of $134,000 during Q4 2020.
- For the 3-year period, Candel Therapeutics' Accumulated Depreciation averaged around $876,000, with its median value being $806,500 (2022).
- Data for Candel Therapeutics' Accumulated Depreciation shows a peak YoY skyrocketed of 383.51% (in 2022) over the last 5 years.
- Quarterly analysis of 4 years shows Candel Therapeutics' Accumulated Depreciation stood at $134,000 in 2020, then spiked by 162.69% to $352,000 in 2021, then skyrocketed by 220.74% to $1.1 million in 2022, then spiked by 102.42% to $1.8 million in 2023.
- Its Accumulated Depreciation stands at $1.8 million for Q3 2023, versus $1.6 million for Q2 2023 and $1.4 million for Q1 2023.